ESTRO 2025 - Abstract Book

S1883

Clinical - Urology

ESTRO 2025

Material/Methods: In our prospective national cohort study, patients were invited to complete HRQOL questionnaires at baseline, 12 and 24 months after diagnosis. We included patients with non-metastatic MIBC, treated with either RC or BPT (chemoradiation or EBRT with brachytherapy), who had completed at least one HRQOL questionnaire. HRQOL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC-QLQ-C30, version 3.0) and bladder cancer-specific symptoms were assessed using the EORTC-QLQ-Muscle-Invasive Bladder Cancer (QLQ-BLM30). We used linear mixed-effects models to analyse differences in HRQOL between the two treatment groups (range 0-100). Results: 292 patients completed the baseline questionnaire, 214 patients in the RC group and 78 in the BPT group. Baseline HRQOL scores were similar in both groups. At 24 months, pain scores and emotional functioning were better in the RC group, with a between-group difference of -7.5 (95%CI -12.7 to -2.2) and 6.2 (95%CI 2.0 to 10.5), respectively. In contrast, cognitive function was better in the BPT group, difference of -5.1 (95%CI -9.2 to -1.0). Male sexual symptoms scores and body image scores were better in the BPT group, differences were 25.6 (95%CI 11.2 to 39.9) and 9.3 (95%CI 4.2 to 14.4), respectively. There was no difference in the abdominal bloating and flatulence score, -2.24 (95%CI -7.29 to 2.82). Limitations: patients with lower SES were underrepresented due to non-response. Conclusion: BPT and RC resulted in equal HRQOL scores in most domains. Sexual functioning, body image and cognitive function were significantly better after BPT. RC resulted in better pain scores and emotional functioning. Insights into HRQOL outcomes can be used to guide shared decision making. References: 1. Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021. 2. Brück K, Meijer RP, Boormans JL, Kiemeney LA, Witjes JA, van Hoogstraten LMC, et al. Disease-free survival of patients with muscle invasive bladder cancer treated with radical cystectomy versus bladder preserving therapy: a nationwide study. Int J Radiat Oncol Biol Phys. 2023. 3. Rammant E, Van Wilder L, Van Hemelrijck M, Pauwels NS, Decaestecker K, Van Praet C, et al. Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer: an umbrella review. Qual Life Res. 2020. Keywords: Bladder preservation, Radical cystectomy, QOL

372

Mini-Oral Long-Term Results of Radiotherapy with or without Focal Boost in Patients with Localized Prostate Cancer: A Propensity Score Match Analysis Cem Onal 1,2 , Ozan Cem Guler 1 , Gurcan Erbay 3 , Birhan Demirhan 4 , Aysenur Elmali 2 , Melek Yavuz 2 1 Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana, Turkey. 2 Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey. 3 Department of Radiology, Baskent University Faculty of Medicine, Adana, Turkey. 4 Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkey